3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Prostatic Neoplasms
4
Breast Neoplasms
3
Pancreatic Neoplasms
2
Glioblastoma
2
Smoking Cessation
1
Quality of Life
1
Patient Compliance
1
Overweight
1
Obesity
1
Motor Activity
1
Melanoma
1
Lung Neoplasms
1
Inflammation
1
Glioma
1
GastroEsophageal Cancer
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Advanced Malignant Solid Neoplasm
1
Interventions
Magnetic Resonance Spectroscopy
22
Temozolomide
17
Specimen Handling
13
X-Rays
9
Biopsy
9
Radiotherapy
8
Radiation
8
trametinib
6
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
6
Bevacizumab
6
larotrectinib
4
erdafitinib
4
dabrafenib
4
ulixertinib
3
palbociclib
3
abemaciclib
3
Surgical Procedures, Operative
3
Nivolumab
3
Cyclophosphamide
3
vorasidenib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
olaparib
2
mirdametinib
2
lutetium Lu 177 dotatate
2
ivosidenib
2
fluorodopa F 18
2
fludarabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioma
×
Diet Therapy
×
90 days
×
Clear all
NCT02286167
2026-03-24
GLAD
Wake Forest University Health Sciences
Phase NA
Completed
25 enrolled